Business
HippoFi Finalizes an Exclusive Strategic Partnership with International Biomedical Manufacturing Company, BPB Medica
HippoFi Finalizes an Exclusive Strategic Partnership with International Biomedical Manufacturing Company, BPB Medica.
About this update from Orhub, Inc.
[{"type":"text","content":"PUR Biologics, a HippoFi biotech company, launches PURmarrow360 with BPB Medica, aiming to improve US patient safety and clinical outcomes in the 1.62M annual instrumented spinal fusions.IRVINE, CA / ACCESSWIRE / August 9, 2023 / HippoFi, Inc. (OTCPK:ORHB) a leading healthcare technology company and authority in spinal biologics, executes an exclusive deal with Italian biomedical manufacturing company, BPB Medica. HippoFi's PUR Biologics prepares to launch PURmarrow360 throughout the United States, aiming to provide a safe and simple surgical device, specifically designed to selectively capture a patient's own bone marrow aspirate (BMA) and mesenchymal stem cells (MSCs). Surgeons can combine these valuable, patient specific live-cells with any allograft, allogenic, or synthetic bone substitute during surgery. "The PURmarrow360 system represents a major advancement in capturing MSC's, while eliminating the need for centrifugation, PURmarrow360 also significantly improves patient safety. The advanced technology allows surgeons to efficiently isolate the patient's own live-cells and utilize them to optimize the body's intrinsic osteogenic healing mechanism to facilitate a successful spinal fusion," shared Ryan Fernan, Head of PUR Biologics."The design of PURmarrow360 represents an advancement in the field of stem cell technology and is a safer and a more effective surgical solution than the use of allogenic (cadaver donated) bone grafts containing viable mesenchymal stem cells (MSCs). These cellular bone matrices (CBMs), can carry significant risks which can be eliminated when PURmarrow360 is used as an alternative," explained CJ Wiggins, Executive Chairman and CEO of HippoFi."We are confident in the executive leadership and experience of HippoFi and PUR Biologics and that we have chosen the very best in strategic partners to deliver this unique and one of a kind technology throughout the US market," shared Carlo Bellini, CEO of BPB Medica.Expecting to surpass $3.5B by 2033, the current spinal biologics market is estimated at $2.518B. The proprietary PURmarrow360 innovation is applicable to be used in approximately 91.6% of the 1.62M spinal fusions currently being performed in the US.To learn more about PUR Biologics' full line of biologic products, visit: www.PURbiologics.comAbout PUR BiologicsPUR Bio...